Study study type PathologyT1T0Patientssample sizesROB Results

mBC - TNBC - L1 - all population breast cancer - triple negative mBC - Triple negative (TNBC) - 1st Line (L1) mBC - TNBC - L1 - all population

versus Standard of Care (SoC)
capivasertib plus paclitaxel
PAKT (all population), 2020
  NCT02423603
RCTmBC - TNBC - L1 - all populationcapiversatib plus paclitaxelplacebo plus paclitaxelPatients had histologically confirmed, metastatic or locally advanced TNBC not amenable to curative resection. Previous systemic therapy for locally advanced or metastatic disease was not permitted, but previous adjuvant or neoadjuvant chemotherapy was allowed.70 / 70NA
suggested
  • suggested 39 % decrease in deaths (OS)
  • inconclusive 26 % decrease in progression or deaths (PFS) (PE)